Design essai NEOPAL

1. Newly diagnosed stage II-III BC
   - Biopsy
     - ER+
     - HER2-
     - Ki67
     - Lymph node
   → PAM50
   → Exclude non luminal tumors

2. Luminal A/N+
   - Luminal B
   → R 1:1

3. 18 weeks
   - Letrozole 2.5 mg q1d
   - Palbociclib 125 mg q1d 3w/4
   → Surgery

4. FEC 100 x 3 – docetaxel 100 x 3 q3w

Pathological endpoints
1. RCB
2. pCR - PEPI

Clinical endpoints
1. Clinical response
2. BCS